​

Neurocrine Biosciences (NBIX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NBIX Stock Forecast

Neurocrine Biosciences (NBIX) stock forecast, based on 34 Wall Street analysts, predicts a 12-month average price target of $151.80, with a high of $168.00 and a low of $121.00. This represents a 41.55% increase from the last price of $107.24.

$105 $118 $131 $144 $157 $170 High: $168 Avg: $151.8 Low: $121 Last Closed Price: $107.24

NBIX Stock Rating

Neurocrine Biosciences stock's rating consensus is Buy, based on 34 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 29 Buy (85.29%), 5 Hold (14.71%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 34 0 5 29 Strong Sell Sell Hold Buy Strong Buy

NBIX Price Target Upside V Benchmarks

TypeNameUpside
StockNeurocrine Biosciences41.55%
SectorHealthcare Stocks 30.37%
IndustrySpecialty & Generic Drug Manufacturers Stocks39.28%

Price Target Trends

1M3M12M
# Anlaysts2317
Avg Price Target$163.00$158.67$158.35
Last Closing Price$107.24$107.24$107.24
Upside/Downside52.00%47.96%47.66%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 256155--26
Mar, 256155--26
Feb, 256144--24
Jan, 257154--26
Dec, 248154--27
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 28, 2025Canaccord Genuity$158.00$106.4648.41%47.33%
Apr 22, 2025Andrew FeinH.C. Wainwright$168.00$101.7465.13%56.66%
Mar 07, 2025Morgan Stanley$150.00$113.0432.70%39.87%
Jan 08, 2025Ashwani VermaUBS$162.00$137.5517.78%51.06%
Oct 31, 2024Evan David SeigermanBMO Capital$121.00$120.270.61%12.83%
Oct 22, 2024Jay OlsonOppenheimer$192.00$116.5764.71%79.04%
Oct 10, 2024Danielle BrillRaymond James$155.00$111.6238.86%44.54%
Sep 13, 2024Evan David SeigermanBMO Capital$128.00$122.294.67%19.36%
Sep 09, 2024Carter GouldBarclays$160.00$120.1733.14%49.20%
Aug 29, 2024Brian AbrahamsRBC Capital$136.00$123.769.89%26.82%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 22, 2025H.C. WainwrightBuyBuyhold
Feb 04, 2025Morgan StanleyOverweightOverweighthold
Jan 08, 2025UBSBuyBuyhold
Jan 07, 2025RBC CapitalSector PerformSector Performhold
Oct 29, 2024RBC CapitalMarket PerformMarket Performhold
Oct 22, 2024OppenheimerOutperformOutperformhold
Oct 14, 2024Piper SandlerOverweightOverweighthold
Oct 04, 2024RBC CapitalSector PerformSector Performhold
Sep 13, 2024William BlairOutperformOutperformhold
Sep 13, 2024BMO CapitalMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.37$0.95$1.61$2.56$3.40----
Avg Forecast$1.20$1.78$2.22$2.56$4.05$6.40$8.65$11.24$14.00
High Forecast$1.26$1.87$2.34$2.94$4.34$7.44$11.63$15.31$14.86
Low Forecast$1.12$1.66$2.05$1.72$3.74$4.77$6.06$7.52$12.83
Surprise %264.17%-46.63%-27.48%--16.05%----

Revenue Forecast

$1B $2B $2B $3B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.05B$1.13B$1.49B$1.89B$2.36B----
Avg Forecast$1.06B$1.14B$1.48B$1.89B$2.36B$2.77B$3.24B$3.68B$4.19B
High Forecast$1.10B$1.18B$1.55B$1.90B$2.37B$2.84B$3.26B$3.71B$4.38B
Low Forecast$1.00B$1.08B$1.40B$1.77B$2.34B$2.58B$3.22B$3.65B$3.92B
Surprise %-0.92%-0.35%0.29%-0.12%-0.11%----

Net Income Forecast

$-2B $-800M $-100M $600M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$407.30M$89.60M$154.50M$249.70M$341.30M----
Avg Forecast$1.32B$110.42M$4.14M$249.70M$385.90M$637.97M$898.75M$1.20B$1.41B
High Forecast$1.68B$138.10M$25.12M$1.67B$438.60M$751.03M$1.18B$1.55B$1.50B
Low Forecast$955.82M$82.73M$-16.85M$-1.17B$378.03M$482.22M$611.63M$759.47M$1.30B
Surprise %-69.14%-18.85%3635.85%--11.56%----

NBIX Forecast FAQ

Is Neurocrine Biosciences stock a buy?

Neurocrine Biosciences stock has a consensus rating of Buy, based on 34 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 29 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Neurocrine Biosciences is a favorable investment for most analysts.

What is Neurocrine Biosciences's price target?

Neurocrine Biosciences's price target, set by 34 Wall Street analysts, averages $151.8 over the next 12 months. The price target range spans from $121 at the low end to $168 at the high end, suggesting a potential 41.55% change from the previous closing price of $107.24.

How does Neurocrine Biosciences stock forecast compare to its benchmarks?

Neurocrine Biosciences's stock forecast shows a 41.55% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and outperforming the specialty & generic drug manufacturers stocks industry (39.28%).

What is the breakdown of analyst ratings for Neurocrine Biosciences over the past three months?

  • April 2025: 23.08% Strong Buy, 57.69% Buy, 19.23% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 23.08% Strong Buy, 57.69% Buy, 19.23% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 25.00% Strong Buy, 58.33% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Neurocrine Biosciences’s EPS forecast?

Neurocrine Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $6.4, marking a 88.24% increase from the reported $3.4 in 2024. Estimates for the following years are $8.65 in 2026, $11.24 in 2027, and $14 in 2028.

What is Neurocrine Biosciences’s revenue forecast?

Neurocrine Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $2.77B, reflecting a 17.65% increase from the reported $2.36B in 2024. The forecast for 2026 is $3.24B, followed by $3.68B for 2027, and $4.19B for 2028.

What is Neurocrine Biosciences’s net income forecast?

Neurocrine Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $637.97M, representing an 86.92% increase from the reported $341.3M in 2024. Projections indicate $898.75M in 2026, $1.2B in 2027, and $1.41B in 2028.